Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Accured Expenses (2016 - 2025)

ImmunityBio (IBRX) has disclosed Change in Accured Expenses for 12 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 191.06% to $1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.2 million, a 311.14% increase, with the full-year FY2025 number at $3.2 million, up 311.14% from a year prior.
  • Change in Accured Expenses was $1.9 million for Q4 2025 at ImmunityBio, down from $5.5 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $18.6 million in Q1 2023 to a low of -$19.5 million in Q4 2023.
  • A 5-year average of $882450.0 and a median of $2.6 million in 2024 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 675.33% in 2022, then tumbled 519.36% in 2023.
  • ImmunityBio's Change in Accured Expenses stood at $4.6 million in 2021, then plummeted by 169.13% to -$3.2 million in 2022, then crashed by 519.36% to -$19.5 million in 2023, then surged by 89.17% to -$2.1 million in 2024, then skyrocketed by 191.06% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Change in Accured Expenses are $1.9 million (Q4 2025), $5.5 million (Q3 2025), and $8.7 million (Q2 2025).